Premium
Cell proliferation in colorectal tumor progression: An immunohistochemical approach to intermediate biomarkers
Author(s) -
Risio M.
Publication year - 1992
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.240501115
Subject(s) - ulcerative colitis , immunohistochemistry , proliferating cell nuclear antigen , colorectal cancer , pathology , bromodeoxyuridine , biology , colitis , cell growth , cancer research , adenoma , crypt , abnormality , cancer , medicine , disease , immunology , endocrinology , psychiatry , genetics
Cell renewal in the large intestine mucosa is normally tied to a rigidly compartmentalized model. Immunohistochemical identification of cells in S phase through uptake of bromodeoxyuridine is the method of choice for detailed compartmental mapping of proliferation, while immunohistochemical detection of proliferation‐associated antigens (Ki‐67, PCNA, DNA polymerase α) provides information in advanced tumor cases. Mucosal hyperproliferation due to inflammation may be transient (Self‐limited colitis, Crohn's disease, acute radiation damage) or lasting (ulcerative colitis). Progressive shifting of the proliferation zone to the crypt surface (Stage II abnormality) is a late feature of irradiated rectal mucosa and subgroups of ulcerative colitis patients at high risk for cancer. Hyperproliferation and Stage II abnormality coexist in the mucosa of patients with colorectal neoplasia, but are mutually independent and correlated to different clinical and pathological features of the disease. These cytokinetic abnormalities are highly predictive markers of the adenomacarcinoma sequence, but are not associated with de novo adenocarcinoma. Proliferation increases progressively in the subsequent steps of this sequence, except in early cancer. © 1992 Wiley‐Liss, Inc.